Shots:

• The P- III trial involves assessing of Keytruda in combination with ipilimumab vs Keytruda monothx in 568 patients in a ratio (1:1) as 1L treatment for metastatic NSCLC patients without EGFR or ALK genomic tumor aberrations and whose tumors express PD-L1
• Results: @ median follow-up (20.6 mos.); mOS (21.4 vs 21.9 mos.); mPFS (8.2 vs 8.4 mos.); ORR (45.4%); mDOR (16.1 mos.); RMST ( -0.56 and -0.52) @24 mos.
• The results were presented in the Presidential Symposium at the World Conference on Lung Cancer 2020 Presidential Symposium and published in the Journal of Clinical Oncology

 ­ Ref: Businesswire | Image: Merck